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baseline and follow ups (experienced-Infliximab group, EIG) and those who were
not treated with Infliximab at baseline but went on Infliximab treatment at the
followups (new-Infliximab group, NIG). RESULTS:Of the 427 RApatients, 48 (11.2%)
used Infliximab before, 83%were female, and the average agewas 45 years old. The
average duration of RA was 6 years, with almost 40% patients suffering RA more
than 5 years. At baseline, the mean scores reported from the patients in EIG were:
morning stiffness 31min, pain 45, HAQ 0.65, MCS 47 and PCS 38, which were all
significantly better than patients in NIG. After 14 weeks Infliximab treatment, NIG
patients improved significantly in morning stiffness (-55.6min), pain (-38.5), HAQ
(-0.6), MCS (-16.2) and PCS (-15.6) than baseline (all P0.0001). CONCLUSIONS: RA
patients using Infliximab have better quality of life and daily function activities
than those not using Infliximab before. Our findings also indicate that, it is essen-
tial to continue or initiate treatment with Infliximab to improve outcomes and
quality of life in RA patients in China.
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OBJECTIVES: To report results of HRQOL in Chinese patients with rheumatoid
arthritis (RA) and ankylosing spondylitis (AS). METHODS: Adult patients 18yrs
diagnosed with RA or AS were recruited through referrals by physicians in 11
cities(tier 1 and tier 2 level) in China: Beijing, Shanghai, Guangzhou, Tianjin, Wu-
han, Nanjing, Hangzhou, Shenyang, Chengdu, Taiyuan, and Shijiazhuang. Patients
should have worked and stayed in the city 1yr. Disease severity was classified as
mild, moderate and severe based on physician’s subjective assessment. A Chinese
version of the Short-Form(SF)-36 (version 2) was completed by patients. A norm-
based scoring system developed from Chinese population(Hong Kong) was used to
derive 8 subscales: physical functioning(PF), role-physical(RP), bodily pain(BP), gen-
eral health(GH), vitality(VT), social functioning(SF), role-emotional(RE), andmental
health(MH); and physical and mental component summary(PCS and MCS) scores.
Each score ranges from 0 to 100 with higher scores representing better HRQL.
Descriptive statistics are presented. RESULTS: Adult patients with RA(N250, 94
male and 156 female) and AS(N150, 81 male, 69 female) were enrolled and com-
pleted the SF-36 questionnaire. Overall, patients demonstrated low scores (50) in
all 8 SF-36 subscales, especially in PF (31.316.7 vs 32.415.1), BP(34.79.4 vs
35.08.1) and SF(33.613.3 vs 33.012.8), for RA vs AS, respectively. The PCS and
MCS scores were 35.510.4 and 45.310.4, respectively, in AS patients and
34.711.7 and 46.39.6, respectively, in RA patients. These scores decreased with
increase in disease severity and age, but remained consistent with no significant
differences between men and female. CONCLUSIONS: SF-36 scores in Chinese pa-
tients with RA or AS were lower compared to the general Chinese population with
chronic diseases including cardiovascular disease and diabetes, indicating major
impairment in HRQOL.
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OBJECTIVES: Cost-utility analysis is increasingly important to market access deci-
sions in a growing number of countries including Australia. The ability to attach
utility values to health states is an essential component of cost-utility analysis. The
primary aim of this review was to identify appropriate utility weights in rheuma-
toid arthritis (RA) in Australia. The review also aimed to evaluate existing quality of
life (QoL) measures used in RA and identify the key issues associated with the use
of these measures. METHODS: Systematic methods were used to search the Eng-
lish language literature for studies reporting health-related utilities for RA. The
literature search covered a wide range of electronic databases (EMBASE, Medline,
Cochrane Library), and included literature from the inception of database to Janu-
ary 2012. RESULTS: The search identified 28 studies: 2 from Australia and 26 from
other countries. Both Australian studies reported mean EQ-5D utility values for
Australian patients with RA. One of the Australian studies also found that the HAQ
scores explained more of the variance in the HUI3-derived than EQ-5D-derived
utility weights, and that RA-affected joint counts had negligible explanatory power
for patient utility. Review of the other 26 studies found that a variety of QoL instru-
ments were used. All instruments were found to be valid measures for QoL in
patients with RA and appeared to adequately discriminate across levels of RA
severity. Nevertheless, each instrument revealed strengths and weaknesses,
which prevented the recommendation of one instrument in favour of the other.
CONCLUSIONS: This review of utility weights for RA revealed a high level of un-
certainty about the evidence base that informs cost-utility analyses in this disease
area. There is no conclusive evidence to date as towhichmeasure is the best for use
in RA.
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OBJECTIVES: Despite the fact that non-benzodiazepine hypnotics (Z-drugs) are
beneficial for the short-termmanagement of insomnia, it is inconclusive about the
risk and benefit ratios of long-term use. The aim of this study was to examine the
medication use patterns of Z-drugs and its prescribers in a 2000-bedmedical center
in Taiwan. METHODS: We conducted the medication use evaluation study using
China Medical University Hospital (CMUH) in-house databases. During the whole
year of 2011, those CMUHoutpatients ever prescribedwith zolpidem and zopiclone
were of interest. Their prescription prevalence rate of Z-drugs, its average number
of defined daily dose (DDD), prescriber specialties and demographic characteristics
were examined using descriptive analyses. RESULTS: In 2011, 2,261 and 2,885 pa-
tients were ever prescribed with at least one prescription with zolpidem and zopi-
clone, respectively, in the outpatient units in CMUH. While more female were
prescribed with Z-drugs, 40% of zolpidem users and 32% of zopiclone users were
elderly. Within one year period, the average prescription number of zolpidem and
zolpiclone were 5.474.78 and 4.34.38, respectively. While the average durations
for each prescription were 257 days for zolpidem and 238 days for zolpiclone,
respectively. 25% of zolpidem users and zolpiclone users were prescribed 9 to 43
times and 6 to 52 times, respectively. The top three prescribers were neurologist,
cardiologist, and psychiatrist, which in total had accounted for 63.01% and 46.96%
of zolpidem and zolpiclone prescriber specialties, respectively. CONCLUSIONS:
There is a tendency to have long-termuse of zolpidemand zopiclone among CMUH
outpatients. Those common prescribers of Z-drugs should be warranted for its
consequences of long-term use, especially among the elderly.
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OBJECTIVES: Despite global advancements in disease reporting, the epidemiology
of multiple sclerosis (MS) in Asia is not well reported. MS rates in Asia are low
compared to Europe and North America, but are now thought to be increasing.
Globally, themedian prevalence ofMS is 30/100,000. Our goal is a systematic search
of epidemiologic studies of MS in Asia to determine accurate epidemiologic and
treatment cost estimates. METHODS: This systematic review examined articles
published in English over 20 years using MESH terms: MS, incidence, prevalence,
mortality and costs in any Asian country. Articles with evidence from population-
based samples, based on clinically-defined or laboratory supported MS (e.g., Mc-
Donald criteria) diagnoses, and from major Asian countries were retained. Costs
were the 2008 estimates from the Global Economic Impact of MS. RESULTS: As in
other continents, prevalence in Asia is higher in women than men. In the largest
country, China, prevalence rates of MS are low (1-2/100,000). In Northern Japan, a
much higher prevalence (8.6/100,000) was reported in 2002, an increase from 2.5 in
1975. In Korea, with a population density similar to China, the prevalence was
3.5/100,000, similar to the 3.0/100,000 in Taiwan (2005). Based on an annual cost per
patient of $41,335 (USD international), 2008 estimated costs in China due to MS
exceed $1 billion. In Japan, with 10 times fewer people, the costs exceed $452
million. CONCLUSIONS:Data frommany Asian countries is limited and often from
case-series designed to review clinical characteristics. Larger epidemiological and
cost-based studies in various populations are still needed. Recent evidence sug-
gests a higher prevalence than previously thought, possibly a result of better as-
certainment driven by increased diagnostic awareness. This review supports the
development of effective medications and additional research to better under-
stand the unmet medical need and economic burden driven by MS in Asia.
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OBJECTIVES: Prolonged-release (PR) fampridine is a first-in-class treatment for the
management of walking disability in multiple sclerosis (MS). The purpose of this
study was to evaluate the budget impact of PR-fampridine introduction in the
treatment of MS patients with an Expanded Disability Severity Scale (EDSS) score
between 4.0 and 7.0 in Taiwan.METHODS: A budget impact model was developed
with amonthly cycle Markov-chain to evaluate the cost implications of PR-fampri-
dine use to the Taiwan health care payer. All costs in themodel were sourced from
the Taiwan National Health Insurance formulary and are presented in Taiwan
dollars (NT$). Response rates of 35% and 43%, derived frompivotal Phase III trials of
PR-fampridine, were applied. The budget impact was calculated for a 5-year time
horizon. The base case analysis included the treatment costs of PR-fampridine
only. Sensitivity analyseswere conducted on the impact of PR-fampridine on direct
costs and on market share. RESULTS: For the year 2012, the model estimated 79
patients with EDSS between 4.0 and 7.0 and walking impairment eligible for PR-
fampridine treatment. Budget impact after the introduction of PR-fampridine us-
ing a patient response rate of 35% was NT$241,000 rising to NT$3,225,000 over the
5-year time horizon. Applying a 43% response rate resulted in a budget impact of
NT$285,000 in 2012which equates to a 3.61% increase in spending. CONCLUSIONS:
Walking difficulty is one of themost commonly reported disabilities inMS patients
and PR-fampridine is the only medication indicated for symptom alleviation. The
introduction of PR-fampridine leads to a manageable budget impact in Taiwan as
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